Articles
340B Drug Pricing Program
New Error-Ridden 340B Study Misses the Mark
By Bharath Krishnamurthy, Director, Health Analytics & Policy, Aimee Kuhlman, VP Advocacy Grassroots, Government Relations
A new study published in the New England Journal of Medicine demonstrates a stunning lack of understanding of the 340B drug pricing program and the overall landscape of drug pricing.
340B Drug Pricing Program
Restoring the 340B OPPS Payment Policy: Good for Patients, Good for Providers
By Bharath Krishnamurthy, Director, Health Analytics & Policy, Aimee Kuhlman, VP Advocacy Grassroots, Government Relations
In July, the Centers for Medicare & Medicaid Services published its annual outpatient prospective payment system regulation.